Terbinafin Tedavisi Alan Onikomikoz Hastalarında Koku Duyusunun Değerlendirilmesi

Year 2021, Volume: 23 Issue: 3, 294 - 298, 30.12.2021

Mualla Polat , Tekden Karapınar , Belgin Küçükyangöz Yusuf Özgür Biçer , Özge Uzun Tuna Sezer

https://doi.org/10.18678/dtfd.1010177

Abstract

Amaç: Terbinafinin en sık karşılaşılan yan etkileri gastrointestinal şikayetlerdir. Tat ve koku kaybı yan etkisi ise az sayıda vaka sunumunda bildirilmiştir. Bu çalışmadaki amacımız terbinafinin koku duyusu üzerine etkisini ve koku duyusundaki değişimin derecesini ölçmektir.
Gereç ve Yöntemler: Terbinafin tedavisi başlanan hastalara ve kontrol grubuna koku tanımlama testi (KTT; odor identification test, OIT), koku duyarlılık testi (KDT; odor threshold test, OTT) ve koku ayırım testi (KAT; odor discrimination test, ODT) uygulandı. Koku testi “Sniffin Sticks” test kalemleri ile yapıldı. Hasta grubuna koku testi terbinafin tedavisi başlamadan hemen önce ve 3 aylık tedavi süresinin sonunda yapıldı.
Bulgular: Hasta ve kontrol grupları arasında yaş (p=0,991) ve cinsiyet (p=0,811) açısından istatistiksel olarak anlamlı bir fark saptanmadı. Hasta grubunun başlangıç koku testleri ve kontrol grubunun koku testleri karşılaştırıldığında da aralarında istatistiksel olarak anlamlı bir fark yoktu. Hasta grubunun KTT değeri tedavi başlangıcında 10,15±1,43 ve tedavi sonunda ise 10,10±1,15 olarak saptandı (p=0,743). KDT değerleri tedavi başlangıcında 6,23±1,08 ve tedavi sonunda ise 6,21±0,85 olarak tespit edildi (p=0,811). KAT değerleri tedavi başlangıcında 9,71±1,44 ve tedavi sonunda ise 9,69±1,34 olarak saptandı (p=0,767). Tedavi başında ve sonunda yapılan test sonuçlarında istatistiksel olarak anlamlı bir fark yoktu.
Sonuç: Sistemik terbinafin tedavisinin 3 ay süreyle kullanımına bağlı olarak koku duyusu üzerinde herhangi bir yan etki tespit edilmemiştir.

Keywords

Terbinafin, onikomikoz, Sniffin’Sticks test, koku

Supporting Institution

Bolu Abant İzzet Baysal üniversitesi BAP

Evaluation of Sense of Smell in Onychomycosis Patients Receiving Terbinafine Treatment

Abstract

Aim: The most common side effects of terbinafine are gastrointestinal symptoms. Loss of taste and smell side effects are presented in a small number of case reports. We aimed to measure the effect of terbinafine on the sense of smell and the degree of change in the sense of smell in this study.
Material and Methods: Odor identification test (OIT), odor threshold test (OTT), and odor discrimination test (ODT) were applied to the patients treated with terbinafine and the control group. It was applied with “Sniffin Sticks” test pens. Smell test was performed on the patient group just before the start of terbinafine treatment and at the end of 3 months of treatment.
Results: There was no statistical difference between the patient and control groups in terms of age (p=0.991) and gender (p=0.811). There was no statistical difference when the initial odor tests of the patient group and the control group were compared. The OIT value of the patient group was 10.15±1.43 at the beginning and 10.10±1.15 at the end of the treatment (p=0.743). The OTT values were 6.23±1.08 at the beginning and 6.21±0.85 at the end of the treatment (p=0.811). The ODT values were 9.71±1.44 at the beginning and 9.69±1.34 at the end of the treatment (p=0.767). There was no statistical difference in the results of the tests performed at the beginning and end of the treatment.
Conclusion: There was no adverse effect on the sense of smell associated with the use of systemic terbinafine treatment for 3 months.

Keywords

Terbinafine, onychomycosis, Sniffin’Sticks test, odor

References

• Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs. 1992;43(2):259-84.
• Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol. 1992;126(Suppl 39):61-9.
• Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27(3):267-72.
• Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol. 1998;139(4):747-8.
• Beutler M, Hartmann K, Kuhn M, Gartmann J. Taste disorders and terbinafine. BMJ. 1993;307(6895):26.
• Thuerauf N, Reulbach U, Lunkenheimer J, Lunkenheimer B, Spannenberger R, Gossler A, et al. Emotional reactivity to odors: olfactory sensitivity and the span of emotional evaluation separate the genders. Neurosci Lett. 2009;456(2):74-9.
• Aschenbrenner K, Scholze N, Joraschky P, Hummel T. Gustatory and olfactory sensitivity in patients with anorexia and bulimia in the course of treatment. J Psychiatr Res. 2008;43(2):129-37.
• Swiecicki L, Zatorski P, Bzinkowska D, Sienkiewicz-Jarosz H, Szyndler J, Scinska A. Gustatory and olfactory function in patients with unipolar and bipolar depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):827-34.
• Cingoz ID, Kizmazoglu C, Guvenc G, Sayin M, Imre A, Yuceer N. Evaluation of the olfactory function with the "Sniffin' Sticks" test after endoscopic transsphenoidal pituitary surgery. J Craniofac Surg. 2018;29(4):1002-5.
• Tuccori M, Lapi F, Testi A, Ruggiero E, Moretti U, Vannacci A, et al. Drug-induced taste and smell alterations: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2011;34(10):849-59.
• Lemont H, Sabo M. Terbinafine-associated taste disturbance with normal taste threshold scores. J Am Pediatr Med Assoc. 2001;91(10):540-1.
• Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case control study of potential risk factors. Br J Clin Pharmacol. 1996;42(3):313-8.
• Doty RL, Haxel BR. Objective assessment of terbinafine induced taste loss. Laryngoscope. 2005;115(11):2035-7.
• Boesveldt S, Postma EM, Boak D, Welge-Luessen A, Schöpf V, Mainland JD, et al. Anosmia-A clinical review. Chem Senses. 2017;42(7):513-3.
• Horger S, Kandrac S, Longyhore DS. Taste and smell disturbance resulting from midodrine. J Pharm Pract. 2016;29(6):571-3.
• Hummel T, Nordin S. Olfactory disorders and their consequences for quality of life. Acta Otolaryngol. 2005;125(2):116-21.
• Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(1):39-52.
• Kobal G, Klimek L, Wolfensberger M, Gudziol H, Temmel A, Owen CM, et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol. 2000;257(4):205-11.
• Landis BN, Hummel T. New evidence for high occurrence of olfactory dysfunctions within the population. Am J Med. 2006;119(1):91-2.
• Tekeli H, Altundağ A, Salihoğlu M, Cayönü M, Kendirli MT. The applicability of the ‘‘Sniffin’ Sticks’’ olfactory test in a Turkish population. Med Sci Monit. 2013;19:1221-6.
• Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014;36(4):679-83.
• Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2-7.
• Koch A, Tchernev G, Wollina U. Allergic maculo-papular exanthema due to terbinafine. Open Access Maced J Med Sci. 2017;5(4):535-6.
• Cohen PR, Erickson CP, Calame A. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. Dermatol Online J. 202015;26(7):13030/qt9jh9p0xp.
• Mayser P. Terbinafine: Drug-induced lupus erythematodes and triggering of psoriatic skin lesions. Hautarzt. 2016;67(9):724-31. German.